Last reviewed · How we verify
PIPAC with systemic chemotherapy
At a glance
| Generic name | PIPAC with systemic chemotherapy |
|---|---|
| Sponsor | Association Francaise de Chirurgie |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial (PHASE2)
- Treatment of Malignant Peritoneal Mesothelioma (MESOTIP) (PHASE2)
- A Prospective, Safety, and Efficacy Clinical Trial of Pressurized Intraperitoneal Aerosol Therapy for Peritoneal Metastasis of Colorectal Cancer (PHASE1)
- Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients With Peritoneal Metastasis From Pancreatic Adenocarcinoma (PHASE1)
- PIPAC and FOLFOX for Gastric Cancer Peritoneal Cancer (NA)
- Prophylactic PIPAC in Patients With High-risk Colorectal Cancer (PHASE3)
- PIPAC in Multimodal Therapy for Patients with Oligometastatic Peritoneal Gastric Cancer (PHASE3)
- The Safety and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy for Peritoneal Metastatic Adenocarcinoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |